Matt Zuga - Jan 18, 2024 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role
CFO & Chief Business Officer
Signature
/s/ Derek Meisner, Attorney-in-Fact
Stock symbol
ABOS
Transactions as of
Jan 18, 2024
Transactions value $
-$15,717
Form type
4
Date filed
1/19/2024, 07:05 PM
Previous filing
Jan 4, 2024
Next filing
Jun 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABOS Common Stock Sale -$15.7K -4.24K -1.97% $3.71 211K Jan 18, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2023.